mRNA-1345 for Respiratory Syncytial Virus (RSV) in 7MM: Market Size, Forecasts, and Emerging Insights 2019-2032 – ResearchAndMarkets.com




mRNA-1345 for Respiratory Syncytial Virus (RSV) in 7MM: Market Size, Forecasts, and Emerging Insights 2019-2032 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “mRNA-1345 Market Size, Forecast, and Emerging Insight – 2032” report has been added to ResearchAndMarkets.com’s offering.

“mRNA-1345 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about mRNA-1345 for Respiratory syncytial virus (RSV) in the seven major markets. A detailed picture of the mRNA-1345 for RSV in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the mRNA-1345 for RSV.

The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the mRNA-1345 market forecast analysis for RSV in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in RSV.

Drug Summary

The mRNA-1345 vaccine is a messenger RNA (mRNA) vaccine. This mRNA is entirely made in a laboratory and instructs the body to build small pieces of proteins. Moderna’s mRNA-1345 RSV vaccine candidate encodes for a prefusion F glycoprotein, eliciting a superior neutralizing antibody response.

In this case, the vaccine candidate contains the mRNA code for the RSV glycoprotein F, which does not cause RSV infection but helps the body’s immune system recognize and protect itself if it encounters the virus. Therefore, one cannot become infected with RSV by receiving the investigational vaccine. The mRNA-1345 RSV vaccine candidate prevents illness from RSV, a leading cause of respiratory illness in young and older adults (65+). Currently, the drug is in Phase III for older adults. mRNA-1345 is also ongoing in a Phase I trial in pediatric populations; RSV is also a large burden in the pediatric population.

RSV program has endorsed the start of the Phase III portion of the pivotal clinical study of mRNA-1345, the Company’s Respiratory Syncytial Virus (RSV) vaccine candidate, in adults 60 years and older. The DSMB’s endorsement comes after independent review of preliminary Phase II data, which suggest that the vaccine has an acceptable safety profile in older adults at the selected dose. This study is known as ConquerRSV.

mRNA-1345 Analytical Perspective

In-depth mRNA-1345 Market Assessment

This report provides a detailed market assessment of mRNA-1345 for Respiratory syncytial virus (RSV) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

mRNA-1345 Clinical Assessment

The report provides the clinical trials information of mRNA-1345 for RSV covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Respiratory syncytial virus (RSV) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence mRNA-1345 dominance.
• Other emerging products for RSV are expected to give tough market competition to mRNA-1345 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of mRNA-1345 in RSV.
• Our in-depth analysis of the forecasted sales data of mRNA-1345 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the mRNA-1345 in RSV.

Key Topics Covered:

1. Report Introduction

2. mRNA-1345 Overview in RSV

2.1. Product Detail

2.2. Clinical Development

2.2.1. Clinical studies

2.2.2. Clinical trials information

2.2.3. Safety and efficacy

2.3. Other Developmental Activities

2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. mRNA-1345 Market Assessment

5.1. Market Outlook of mRNA-1345 in RSV

5.2. 7MM Analysis

5.2.1. Market Size of mRNA-1345 in the 7MM for RSV

5.3. Country-wise Market Analysis

5.3.1. Market Size of mRNA-1345 in the United States for RSV

5.3.2. Market Size of mRNA-1345 in Germany for RSV

5.3.3. Market Size of mRNA-1345 in France for RSV

5.3.4. Market Size of mRNA-1345 in Italy for RSV

5.3.5. Market Size of mRNA-1345 in Spain for RSV

5.3.6. Market Size of mRNA-1345 in the United Kingdom for RSV

5.3.7. Market Size of mRNA-1345 in Japan for RSV

6. SWOT Analysis

7. Analysts’ Views

8. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/bccnqi

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900